Dr Neeta Somaiah talks to ecancer at ASCO 2026 about findings from the phase I/Ib StrateGIST 1 study evaluating velzatinib in patients with advanced or metastatic gastrointestinal stromal tumours (GIST).

The study demonstrated clinical activity across multiple primary and secondary KIT mutations, including those associated with resistance to existing tyrosine kinase inhibitors. Researchers also observed substantial reductions in circulating tumour DNA and particularly encouraging outcomes in patients with KIT exon 9 mutations.

Dr Somaiah notes that the findings support the ongoing phase III StrateGIST 3 trial evaluating velzatinib in the second-line setting.